Organon price to free cash flow OGN
Market value divided by free cash flow over the last twelve months, since 2022.
- Today, Nov 2, 2026
- 5.4×
- 5-year median
- 6.4×
- Against its 5-year history
- 38th
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 2.3× to 18.3×
- Peer median
- 38.7×
Organon's price to free cash flow is 5.4× as of Nov 2, 2026.
That is below its 5-year median of 6.4×, close to the middle of its last 5 years.
Over that time it ranged from 2.3× in Dec 2025 to 18.3× in Jan 2023.
The median for 10 large drugmakers of a similar size is 38.7×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 5.4× | 2.4× | 6.4× |
| 2025 | 2.4× | 2.3× | 5.5× |
| 2024 | 5.2× | 5.0× | 11.2× |
| 2023 | 8.5× | 6.5× | 18.3× |
| 2022 | 15.9× | 4.2× | 15.9× |
Against its peers
Companies in Drug Manufacturers - General nearest Organon's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| OGNOrganon | 5.4× |
| LQDALiquidia | 24.9× |
| ARQTArcutis Biotherapeutics | 100× |
| INDVIndivior Pharmaceuticals | 138× |
| NRIXNurix Therapeutics | 7.6× |
| PBHPrestige Consumer Healthcare | 10.0× |
| HRMYHarmony Biosciences | n/m |
| LGNDLigand Pharmaceuticals | 46.6× |
| AMRXAmneal Pharmaceuticals | 51.1× |
| KNSAKiniksa Pharmaceuticals International | 38.7× |
| ALKSAlkermes plc. | 34.0× |
| Peer median | 38.7× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on Organon
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.